NanoString Technologies, which focuses on molecular diagnostics and translational life sciences systems, looks to obtain up to $77.6 million in an initial public offering. The Seattle company will use part of the proceeds to market its Prosigna Breast Cancer assay.
Wash. molecular Dx firm targets up to $77.6M from IPO
SmartBrief Job Listings for Health Care
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Staff VP Medical Policy Development-81321||
|Strategic Partner Relationship Executive||
Geisinger Health System